Member Info for Parob

Mizman, Due to the recent rapid rise and huge potential that N4 has, there’s now a lot of interest in this stock and imo momentum alone could drive the price back up but here are some POTENTIAL share price catalysts: - Nuvec point of difference study news. - Sildenefil human trials at Glasgow Royal Infirmary - commencement/update and/or results. - Further collaborations for Nuvec. - Broker upgrade to their share price target. - Final results - Aim_Chaos/Myles updated research/Nuvec modelling note. - Being tipped in the media/tipster websites. - Further holdings RNS/Institutional buying. - News on other patents. - News on other drugs being reformulated. - News on further grants. - Media coverage of any news listed above.

At 15p the market cap would be just £13 million which seems ludicrous when you consider what N4 has going for it - not one, but two potential game changers at the moment, and the potential for others in the future. Should the price hit that level I would imagine there’d be huge buying pressure. The share price was around 20p BEFORE the Japan and AZ/MedImmune RNS. We must be very close to the bottom and I envisage the reversal will be pretty powerful once it kicks in imo.

Shouldn’t have to wait too long for Sildenafil news. From the last RNS: “Whilst the Company awaits the imminent commencement of pilot human trials for its reformulation of sildenafil” Would expect some decent media coverage on the back of that RNS, especially with the recent switch to OTC status.

...that the trend has changed buyers in volume will move back in. Many will be sat on the sidelines waiting. We can’t be too far off the bottom as the market cap’s back to just £18 million, less than when N4 struck the partnership with AZ! We seem to have good support around the 20p level.

Great find Leister. The news was covered in quite a few media outlets including the The Daily Mail: Could VIAGRA prevent bowel cancer? Study claims a small daily dose of the little blue pill HALVES the risk of forming dangerous cells http://www.dailymail.co.uk/health/article-5518669/Could-VIAGRA-prevent-colorectal-cancer.html Gives you an indication of what the media attention will be like once N4’s Sildenafil news starts flowing.

As we know N4P have two potential game changers at the moment, Sildenafil and Nuvec. If we knew right now that either is a dead cert for success the share price would already be in the pounds imo. That is the risk reward. With N4P we have multiple shots at the goal, we’re not just dependent on one product. Everything is going to plan so far - in fact the AZ collaboration was ahead of the company’s anticipated schedule. Over the course of 2018 we will have a good idea if Nuvec or Sildenafil (hopefully both!) will be game changers. It’s a very exciting share to be in, that’s for sure.

Marco, Not sure if Hugh is referring to this but follow up takes place between March – June 2018 according to this: http://www.investsefton.com/global-business-accelerator-programme-cell-gene-therapy-visit-japan/

There is a good chance the price will go back up as quickly as it came down. I could understand it if there had been bad news, but we’ve had the opposite! From the Nuvec RNS: Whilst there are currently NO APPROVED PRODUCTS which use nanosilica as a drug delivery vehicle, the total market size for nanotechnology drug delivery was valued at $79 billion in 2012 and is expected to reach a value of $178 billion in 2019, representing a compound annual growth rate of 4.15%

N4P is not in the microbiome sector. If you’re interested in that space take a look at Optibiotix who have recently started to commercialise products with partners and they’re on the market now.

The Bio-Spring Europe conference ended yesterday, so we could hear partnering news on the back of that or Japan in the near future. I'm sure N4 will be attending plenty of other conferences over the course of the year now they're in full marketing mode. I like their two-fold development strategy for Nuvec as I imagine partners will evaluate the Nuvec system at no or little cost to N4.

It seems the Nuvec RNS has now been absorbed, what followed was an unjustified sell off IMO. Hopefully onwards and upwards from here with a steady and fairly swift recovery.

I grabbed a few at 21.2p this morning. This is now oversold and I bet there are many investors wanting to buy in but just waiting for the trend to change before they hit the buy button.

Anyone who was put off from investing by pettycash’s negativity last summer when the price was 5p has missed out on a small fortune here.

Pettycash, I take it you've read all the RNS? "N4P have a chance, and maybe a good one, but I wouldn't expect a partnership to jump out as readily or easily as you might think." The MedImmune/AZ partnership was announced early FeB and much earlier than many expected. "We continue to make great progress with our Nuvec(R) particles and we believe that MedImmune is the ideal partner to evaluate our nanoparticles in this field."

Bio-Europe Spring Partnering Conference. From tomorrow until Weds: https://ebdgroup.knect365.com/bioeurope-spring/partnering MEET THE RIGHT PEOPLE AND ACHIEVE YOUR GOALS THROUGH ONE-TO-ONE MEETINGS partneringONE® is the gold standard solution for your meetings Access to partnering is granted once registration is approved. HOW TO USE THE PARTNERING SYSTEM Our proprietary partnering platform, partneringONE, allows you to identify prospective partners using advanced search capabilities and manage all your meeting requests in one place. Arrive onsite with a pre-filled, personalized meeting schedule.

The price action on Friday carved out a bullish hammer (or hammer-like) candlestick pattern which may indicate an upside reversal.

A good synopsis of Thursday's RNS https://tinyurl.com/y7ycheqa � The Company provided investors with an update on its Nuvec� program. N4 Pharma CEO, Nigel Theobold, confirmed his Board�s intention is to undertake relevant research and pre-clinical work that will prospectively allow Nuvec� to enter human clinical studies with a partner by the end of 2020. � A two-fold development strategy has been outlined. Firstly, the Company is proactively looking to work with partners to evaluate its Nuvec� drug delivery system with their products. Recently, for example, N4 Pharma announced a partnership with MedImmuneUK, a leading global biologics R&D company, to explore the manufacture of a prototype nanomedicine using the Nuvec� system. The Company is looking for additional partnerships in due course. A recent trip to Japan was also successful in providing useful introductions to further potential partners which will be progressed over the coming months. Secondly, the Company has embarked on an internal research programme to expand the dataset required to advance Nuvec� towards commercialisation. The Board's strategy is designed to determine precisely how Nuvec� will be used by its partners, either as a vaccine, a delivery system for therapeutics, or both. � N4 Pharma recently commissioned a market research report from Agility Health Tech to assess the potential market position for Nuvec�. While there are currently no approved products which use nanosilica as a drug delivery vehicle, the total market size for nanotechnology drug delivery was valued at US$79b in 2012, which is expected to expand to as much as US$178b in 2019. � In its new release, N4 Pharma also confirmed the appointment of a highly experienced scientist, Andrew Leishman, as the Head of Nuvec� Development.

It's worth watching this Vox Markets podcast from the 1st March: https://tinyurl.com/ybvbnn3h From 9 mins 10 seconds, Nicola Duke said she expected a one third pullback from the recent high to 23.5/23.9/24p and "then we should see another leg higher and next time we continue higher we're looking for 46 or 53 on the upside".

House broker finnCap said it was encouraged by the announcement, which continues to demonstrate the company’s ability to attract high calibre, global partners, and eager to use the potential inherent within LPLDL. “We expect further announcements for regions in which OPTI products can help differentiate and expand existing marketing products,” the broker said. hTTps://tinyurl.com/yag9ltek

Sacco released an app yesterday: https://www.saccosystem.com/n/en/news/sacco-system-goes-mobile-stay-connected-/263/ There is a whole section/brochure dedicated to LP-LDL. To view it go to App Store, download the ‘Sacco System’ app, then scroll through to page 30 to see the LP-LDL Brochure.